MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.65
+0.62
+2.38%
Closed 16:00 01/26 EST
OPEN
26.08
PREV CLOSE
26.03
HIGH
28.19
LOW
25.75
VOLUME
305.45K
TURNOVER
--
52 WEEK HIGH
43.41
52 WEEK LOW
20.30
MARKET CAP
513.78M
P/E (TTM)
-10.3463
1D
5D
1M
3M
1Y
5Y
When Can We Expect A Profit From Albireo Pharma, Inc. (NASDAQ:ALBO)?
We feel now is a pretty good time to analyse Albireo Pharma, Inc.'s ( NASDAQ:ALBO ) business as it appears the company...
Simply Wall St. · 01/19 09:26
Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might tr...
Zacks · 01/12 15:00
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.
Zacks · 01/12 14:40
Albireo increases 2021 Bylvay sales guidance
Albireo Pharma (ALBO +6.5%) has updated guidance for Bylvay net sales, cash and the two Phase 3 clinical studies. Global Bylvay net sales in 2021 are expected to be $6M-7M,
Seekingalpha · 01/05 14:32
BRIEF-Albireo Pharma Inc - Updated Guidance For Bylvay Net Sales, Cash And The Two Phase 3 Clinical Studies
reuters.com · 01/05 13:56
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.
Benzinga · 12/27/2021 16:12
Albireo Announces Topline Data From Phase 1 Study Of A3907; Says Study Achieved Both Primary And Secondary Objectives, Was Safe And Well Tolerated
– First oral, systemic ASBT inhibitor was safe and well tolerated   – Secondary and exploratory objectives show favorable pharmacokinetics and systemic exposure, while providing target engagement
Benzinga · 12/16/2021 13:37
Albireo Announces Positive Topline Data from Phase 1 Study of A3907
– First oral, systemic ASBT inhibitor was safe and well tolerated – Secondary and exploratory objectives show favorable pharmacokinetics and systemic exposure, while providing target engagement signals – Company on track to initiate planned adult liver dis...
GlobeNewswire · 12/16/2021 13:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALBO. Analyze the recent business situations of Albireo Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALBO stock price target is 76.80 with a high estimate of 84.00 and a low estimate of 68.00.
High84.00
Average76.80
Low68.00
Current 26.65
EPS
Actual
Estimate
-1.110.081.262.44
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 133
Institutional Holdings: 18.30M
% Owned: 94.94%
Shares Outstanding: 19.28M
TypeInstitutionsShares
Increased
38
780.50K
New
4
34.55K
Decreased
29
699.30K
Sold Out
9
405.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Independent Director
David Chiswell
President/Chief Executive Officer/Director
Ronald Cooper
Chief Financial Officer/Treasurer
Simon Harford
Chief Human Resource Officer
Michelle Graham
Chief Scientific Officer
Jan Mattsson
General Counsel/Secretary
Jason Duncan
Other
Martha Carter
Other
Constantine Chinoporos
Other
Pamela Stephenson
Independent Director
Michael Gutch
Independent Director
Anne Klibanski
Independent Director
Stephanie Okey
Independent Director
Davey Scoon
No Data
About ALBO
Albireo Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay (odevixibat), developed for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) and elobixibat, developed for the treatment of chronic constipation, a Phase I product candidate and multiple preclinical candidates. Bylvay is also in Phase III development for the treatment of biliary atresia and Alagille syndrome (ALGS). It also has a preclinical program in adult liver and viral diseases. Its lead preclinical candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT). Its lead candidate for adult viral and liver diseases is A2342, an oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor.

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.